A New Method to Quantify Population Variability for Toxicity Testing
Historically, toxicity testing has been conducted by giving lab animals high doses of chemicals and observing them for adverse events. But quantifying the risks chemicals pose to humans based on animal studies is problematic as the chemical doses are often orders of magnitude higher than environmental levels. Moreover, this process is slow, expensive, and ethically questionable. High-throughput in vitro screening (HTS) is gaining acceptance as an approach to toxicity testing that is efficient, economical, and humane. To fully leverage HTS to assess the risks chemicals pose to human health requires also considering the variability in responses to chemicals due to pharmacokinetic (PK) or pharmacodynamic (PD) differences among life-stages and subpopulations. In this webinar, Dr. Barbara Wetmore of the Hamner Institute discussed how she led a team of Hamner, EPA, and Certara researchers to develop a new toxicity paradigm that estimates chemical-specific PK variability across multiple life-stages and subpopulations.